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1. Introduction
Magnetic nanoparticles (NPs) have many interesting bio-
medical applications.[1–5] They have been used as contrast
agents for magnetic resonance (MR) imaging and colloidal
mediators for magnetic hyperthermia of cancer.[6] One major
issue related to cancer applications of NPs is the lack of specific
binding of NPs to cancer cells. In order to achieve the specific
targeting of cancer cells, various proteins such as transfer-
rin,[7–10] herceptin,[11,12] and chlorotoxin[13] have been conjugat-
ed onto iron oxide NP surfaces. The applied protein ligands dis-
play inherent immunogenecity. The specific ligand-receptor or
antibody-antigen interaction occurs on the cell membrane,
thereby limiting the intracellular uptake of conjugated
NPs.[11,12] It is believed that these disadvantages can be over-
come by using a small molecular weight ligand linked to iron
oxide NPs. Several groups have investigated the conjugation of
folic acid (FA) onto iron oxide NPs for targeting cancer
cells.[14–16] The conjugation methods employed have involved
complicated multi-step synthesis and modification procedures.
In most cases, this has made it difficult to simultaneously cou-
ple other molecules onto iron oxide NP surfaces to achieve
multifunctionalities. Therefore, the fabrication of targeted iron
oxide NPs that also have conjugated drug or imaging molecules
remains a challenge.
One approach relevant to NP surface modifications is the
electrostatic layer-by-layer self-assembly technique[17–19] that
allows the creation of ultra-thin functional films on NP sur-
faces.[20–24] The biofunctionality of the NPs is able to be tuned
by deposition of functional polyelectrolytes or biomacromole-
cules on the NP surfaces.[25,26] For example, Wang et al con-
structed CdTe quantum dot/polyelectrolyte (PE) multilayers
onto polystyrene microparticles, followed by an assembly of an
outermost layer of anti-immunoglobulin for subsequent immu-
nosensing.[25] Caruso and co-workers demonstrated that the
biotin-functionalized Au NP/polyelectrolyte-coated latexes ter-
minated by FI-anti-biotin IgG can be used for homogeneous,
competitive fluorescence quenching immunoassay of biotin
molecules.[26] In another recent work of the same group, it is
shown that multilayered sub-micrometer sized polystyrene par-
ticles modified with a humanized A33 monoclonal antibody
can specifically target A33 antigen-expressing LIM1215 color-
ectal cancer cells.[27]
Recent advances in dendrimer chemistry show that
poly(amidoamine) (PAMAM) dendrimers can be covalently
linked with defined numbers of targeting ligands, imaging dyes,
and drugs, thus providing a platform for the specific targeting,
imaging, and treatment of cancer.[28–32] We here attempt to
combine the unique features of dendrimer chemistry with the
versatile, LbL self-assembly technique that provides a facile
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We demonstrated a unique approach that combines a layer-by-layer (LbL) self-assembly method with dendrimer chemistry
to functionalize Fe3O4 nanoparticles (NPs) for specific targeting and imaging of cancer cells. In this approach, positively
charged Fe3O4 NPs (8.4 nm in diameter) synthesized by controlled co-precipitation of Fe
II and FeIII ions were modified with a
bilayer composed of polystyrene sulfonate sodium salt and folic acid (FA)- and fluorescein isothiocyanate (FI)-functionalized
poly(amidoamine) dendrimers of generation 5 (G5.NH2-FI-FA) through electrostatic LbL assembly, followed by an acetylation
reaction to neutralize the remaining surface amine groups of G5 dendrimers. Combined flow cytometry, confocal microscopy,
transmission electron microscopy, and magnetic resonance imaging studies show that Fe3O4/PSS/G5.NHAc-FI-FA NPs can
specifically target cancer cells overexpressing FA receptors. The present approach to functionalizing Fe3O4 NPs opens a new







approach to fabricating multifunctional iron oxide NPs for tar-
geting and imaging of cancer cells. To accomplish this, we as-
sembled iron oxide NPs with a polyelectrolyte (polystyrene sul-
fonate sodium salt, PSS) and a generation 5 PAMAM
dendrimer prefunctionalized with FA and fluorescein iso-
thiocyanate (FI) moieties (G5.NH2-FI-FA) on the surface of
iron oxide NPs using the LbL self-assembly technique. The
PSS/G5.NH2-FI-FA bilayer-coated iron oxide NPs were then
subjected to an acetylation reaction to neutralize the remaining
terminal amine groups of the dendrimers (Fig. 1). The formed
FI- and FA-functionalized iron oxide NPs display very high
specific binding affinity to cancer cells overexpressing FA re-
ceptors (FAR), as demonstrated by flow cytometry, confocal
microscopy, transmission electron microscopy (TEM), and MR
imaging. To our knowledge, this is the first example of the
fabrication of multifunctional iron oxide NPs by combining the
LbL self-assembly technique with dendrimer chemistry.
2. Results and Discussion
2.1. Characterization of Functionalized Iron Oxide
Nanoparticles
The magnetic iron oxide (Fe3O4) NPs were synthesized by
controlled co-precipitation of Fe II and Fe III ions according to
the literature.[33] The synthesized Fe3O4 NPs (8.4 ± 1.4 nm in di-
ameter as verified by TEM) are positively charged (zeta poten-
tial = +42.02 mV), which allows the subsequent self-assembly
of a negatively charged PSS polyelectrolyte followed by a posi-
tively charged G5.NH2-FI-FA or G5.NH2-FI dendrimer. The
Fe3O4/PSS/G5.NH2-FI-FA or Fe3O4/PSS/G5.NH2-FI NPs
formed were subjected to an acetylation reaction to neutralize
the remaining terminal amine groups of the dendrimers
(Fig. 1). Zeta potential measurements were used to monitor
each step of the coating and functionalization of Fe3O4 NPs
(Table 1). The alternating charge reversal of Fe3O4 NPs after
coating with PSS and G5.NH2-FI or G5.NH2-FI-FA dendri-
mers indicates the successful electrostatic assembly. After the
acetylation reaction, the zeta potentials of both Fe3O4/PSS/
G5.NHAc-FI and Fe3O4/PSS/G5.NHAc-FI-FA significantly
decreased due to the conversion of the dendrimer surface
amine groups to acetamide groups. It is interesting to note that
the zeta potentials of neither Fe3O4/PSS/G5.NHAc-FI nor
Fe3O4/PSS/G5.NHAc-FI-FA NPs are close to zero. This im-
plies that some of the dendrimer terminal amines that interact
with PSS polymer chains due to electrostatic interaction cannot
be acetylated. We believe that the few remaining positive
charges of Fe3O4 NPs would not cause significant non-specific
binding with tumor cells, because the outermost surface amines
of dendrimer layer are acetylated. The functionalized Fe3O4
NPs with the bilayer coating and acetylation reaction are
colloidally stable in aqueous solution as well as in cell culture
medium for at least 6 months at concentrations up to
10 mg mL–1. The selection of the bilayer coating in this study is
to demonstrate a concept that the LbL assembly combined
with dendrimer chemistry can be used to functionalize pre-
formed NPs. We also think that several layers’ coating with the
outermost dendrimer layer may be applicable for improving
the mechanical stability of the particles for in vivo studies.
However, more layers’ coating may increase the risk of weak-
ening the colloidal stability of the particles. It is worthwhile to
note that the approach combining the LbL assembly method
with dendrimer chemistry is essential to make the iron oxide
NPs functional biologically. It is known that carboxyl-termi-
nated PAMAM dendrimers can be self-assembled onto iron
oxide nanoparticle surfaces.[34,35] Our unpublished data show
that iron oxide NPs directly modified with carboxyl acid-termi-
nated dendrimers functionalized with FA moieties through
electrostatic interaction do not specifically
bind KB cells overexpressing FA receptors,
presumably due to the carboxyl groups on the
dendrimer surface. Fabrication of iron oxide
NPs with neutral or close to neutral surface
charge is essential to facilitate the specific bind-
ing through receptor-mediated endocytosis.
The self-assembled bilayers of PSS/
G5.NHAc-FI and PSS/G5.NHAc-FI-FA on
Fe3O4 NPs were also characterized by TEM
imaging. The TEM image of PSS/G5.NHAc-
FI-FA-coated Fe3O4 NPs (Fig. 2a) shows that,
after the bilayer self-assembly and chemical
functionalization, the particles display similar
morphology to the ones before self-assembly
(Fig. S4, Supporting Information). The aggre-
gated nanoparticles shown in the TEM image














Figure 1. Schematic representation of the fabrication of targeted iron oxide NPs.
Table 1. Zeta potential values of Fe3O4 NPs after each step modification.
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(Fig. 2) only reflected the dry state of the particles deposited
onto carbon-coated copper grid before TEM experiment,
which is consistent with literature data.[33] The TEM data do
not necessarily verify that the particles aggregate in aqueous
solution. As mentioned above, the functionalized Fe3O4 NPs
are stable in both aqueous solution and cell culture medium. A
negatively stained (phosphotungstic acid) TEM image (Fig. 2b)
clearly shows that all Fe3O4 NPs are surrounded with the bright
rings of the polymer bilayers of PSS/G5.NHAc-FI-FA, further
confirming the successful self-assembly process. PSS/
G5.NHAc-FI-coated Fe3O4 NPs display similar polymer ring
structures to those of PSS/G5.NHAc-FI-FA-coated Fe3O4 NPs
as observed from the negatively stained TEM images (data not
shown).
2.2. Cytotoxicity Assay
The cytotoxicity of the functionalized Fe3O4 NPs was evalu-
ated by fluorescein diacetate (FDA) and propidium iodide (PI)
staining and by observing cell morphology changes after incu-
bation with the Fe3O4 NPs for 96 h. Cell viability data (Fig. S5,
Supporting Information) show that the KB cells (a human
epithelial carcinoma cell line) treated by functionalized Fe3O4
NPs with or without FA conjugation display similar percentage
of FDA positive cells to the KB cells treated by unmodified
Fe3O4 NPs at an Fe concentration of 0–150 lg mL
–1. Phase
contrast microscopy images show that even at an Fe concentra-
tion of up to 150 lg mL–1, KB cells treated with either Fe3O4/
PSS/G5.NHAc-FI or Fe3O4/PSS/G5.NHAc-FI-FA NPs display
the same morphology as those treated with PBS buffer
(Fig. S6, Supporting Information), indicating that the PSS/den-
drimer bilayer functionalized Fe3O4 NPs are biocompatible at
an Fe concentration of up to 150 lg mL–1.
2.3. Flow Cytometry
The FA and the dye FI modified onto the G5 dendrimer sur-
face were used as a targeting ligand and an imaging molecule,
respectively. This affords the functionalized Fe3O4 NPs with
both targeting and imaging functionalities. Folic acid receptor
(FAR) is well known to be overexpressed in several human car-
cinomas including breast, ovary, endometrium, kidney, lung,
head and neck, brain, and myeloid cancers.[36–38] In this study,
KB cells expressing both high- and low-levels of FAR (denoted
as KB-HFAR and KB-LFAR, respectively) were selected
for the intracellular uptake of functionalized Fe3O4 NPs. Fig-
ure 3 illustrates the binding of PSS/G5.NHAc-FI-FA- and
PSS/G5.NHAc-FI-coated Fe3O4 NPs (Fe concentra-
tion = 4.5 lg mL–1) in KB-HFAR and KB-LFAR cells investi-
gated by flow cytometry. It is clear that after binding of
PSS/G5.NHAc-FI-FA-coated Fe3O4 NPs with KB-HFAR cells,
the fluorescence signal significantly increases (Fig. 3a). In con-
trast, PSS/G5.NHAc-FI-modified Fe3O4 NPs without FA con-
jugation display a similar fluorescence signal to the PBS
control, suggesting no measurable binding to KB-HFAR cells.
For KB-LFAR cells, neither Fe3O4/PSS/G5.NHAc-FI nor
Fe3O4/PSS/G5.NHAc-FI-FA NPs display significant binding
(Fig. 3b). This indicates that the binding of the FA-modified
Fe3O4 NPs to KB cells is mediated by the FAR. We also inves-
tigated the dose-dependent cellular uptake of the functional-
ized Fe3O4 NPs (Fig. 3c and d). At an Fe concentration above
2.3 lg mL–1, KB-HFAR cells exposed to Fe3O4/PSS/
G5.NHAc-FI-FA NPs show remarkably higher fluorescence
signals than those treated with Fe3O4/PSS/G5.NHAc-FI NPs
without FA (Fig. 3c). This again implies that the high affinity
of FAR mediates specific uptake of the NPs.
Both Fe3O4/PSS/G5.NHAc-FI and Fe3O4/PSS/G5.NHAc-FI-
FA NPs display much less uptake in KB-LFAR cells than in
KB-HFAR cells, even at an Fe concentration of up to
90 lg mL–1 (Fig. 3d). However, in the studied concentration
range, Fe3O4 NPs with FA conjugation exhibit more uptake in
KB-LFAR cells than those without FA modification, which is
quite different than that of single FA-modified G5 dendri-
mers.[30] It implies that the FA-modified Fe3O4 NPs display
higher binding sensitivity than that of FA-modified G5 dendri-
mers. The higher binding capacity of FA-modified Fe3O4 NPs
may stem from the polyvalency effect due to multiple FA li-
gands presented onto each Fe3O4 NP surface.
[39,40] The number
of FA ligands (n) per Fe3O4 NP can be calculated according to
the following equation:




where r1 and r2 are the radius of PSS-modified Fe3O4 NPs and
G5.NHAc-FI-FA dendrimers, respectively, and n1 is the num-
ber of FA moieties per G5 dendrimer. Note that the calculation
is based on the following assumptions: (1) a densely packed
monolayer of G5.NHAc-FI-FA dendrimer is presented onto
the Fe3O4 NP surfaces; (2) each dendrimer molecule shows a
pancake shape when deposited onto the Fe3O4 NP sur-
faces[41,42] and the diameter of the pancake shape does not
change significantly, compared with that of dendrimers in solu-
tion; (3) the PSS polymer layer thickness is 2 nm;[43] and
(4) there are half the number of FA (2.4) moieties presented in
each dendrimer molecule available for binding (based on the
geometry of dendrimer shape and stochastic distribution of FA
moieties onto each G5.NHAc-FI-FA dendrimer). The number
Adv. Funct. Mater. 2007, 17, 3043–3050 © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.afm-journal.de 3045
Figure 2. TEM images of the PSS/G5.NHAc-FI-FA-coated Fe3O4 NPs.
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of FA moieties per Fe3O4 NPs was calculated to be ∼ 35.6,
using the average diameter of PSS-coated Fe3O4 NPs
(10.4 nm) and G5 dendrimers (5.4 nm).[44] The larger number
of FA moieties per Fe3O4 NP compared with single FA-modi-
fied dendrimer (4.8 FA per dendrimer) facilitates the polyva-
lency effect, thereby significantly increasing the binding affini-
ty of Fe3O4 NPs on each KB cell. It should be noted that in the
in vitro binding experiment, the use of KB-LFAR cells conveys
similar information to the free-FA blocking experiment per-
formed with dendrimer nanodevices in our group.[30,45]
2.4. Confocal Microscopy Observations
The self-assembly of G5.NHAc-FI-FA dendrimers onto
Fe3O4 NPs also affords the utilization of confocal microscopic
imaging of the intracellular uptake of Fe3O4 NPs. It is clear
that after treatment with Fe3O4/PSS/G5.NHAc-FI-FA NPs for
2 h, the green FI fluorescence signals appear in the cytosol of
KB-HFAR cells (Fig. 4c). In contrast, KB-HFAR cells treated
with Fe3O4/PSS/G5.NHAc-FI without FA conjugation do not
show a FI fluorescence signal, similar to the KB-HFAR cells
treated with PBS buffer (Fig. 4a and b). The confocal imaging
data suggest that the intracellular uptake of Fe3O4/PSS/
G5.NHAc-FI-FA NPs into KB-HFAR cells is through the
FAR-mediated endocytosis.
2.5. Transmission Electron Microscopy (TEM) Imaging
The specific intracellular uptake of FA-modified Fe3O4 NPs
was further verified by TEM. The TEM imaging technique al-
lows for clear identification of the Fe3O4 NPs in different cellu-
lar entities. TEM images of KB-HFAR cells treated with
Fe3O4/PSS/G5.NHAc-FI-FA NPs for 2 h show that the NPs
distributed predominantly into the vacuoles of the cells (Fig. 5a
and b), whereas the lyosomes and the nucleus do not show any
uptake of Fe3O4/PSS/G5.NHAc-FI-FA NPs. In contrast, we
did not observe any significant uptake of Fe3O4/PSS/
G5.NHAc-FI NPs without FA modification (Fig. 5c). There
was only minimal uptake of Fe3O4/PSS/G5.NHAc-FI NPs ran-
domly distributed in the vacuoles of some cells (Fig. S7, Sup-
porting Information), which was undetectable using confocal
microscopy. This minimal uptake might be related to diffusion-
3046 www.afm-journal.de © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2007, 17, 3043–3050


















































Figure 3. Binding of Fe3O4 NPs modified with PSS/G5.NHAc-FI and PSS/G5.NHAc-FI-FA bilayers with KB cells. a) KB cells expressing high-level FAR;
and b) KB cells with low-level FAR. 1. PBS control (black line); 2. PSS/G5.NHAc-FI-modifed Fe3O4 NPs (grey line); 3. PSS/G5.NHAc-FI-FA-modifed
Fe3O4 NPs (dotted line). FL1 indicates the green fluorescence signal intensity generated from FI. Dose-dependent binding of functionalized Fe3O4 NPs
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driven non-specific binding since control cells without treat-
ment of Fe3O4 NPs did not show any internalized NPs. The
TEM studies underline the high specificity of FA-modified
Fe3O4 NPs for targeting KB-HFAR cells, in agreement with
the confocal imaging data.
2.6. Magnetic Resonance (MR) Imaging
MR imaging is often used for the diagnosis and staging of
cancer. Iron oxide NPs affect the MR signal by dephasing
transverse magnetization and hence reducing the value of T2.
A targeted iron oxide NP would have a major benefit in cancer
imaging by specifically detecting tumors that over-express the
FAR. To study the effect of Fe3O4/PSS/G5.NHAc-FI-FA NPs
on cancer cells, we measured the T2 of KB-HFAR cells ex-
posed to differing concentrations of Fe3O4/PSS/G5.NHAc-FI-
FA NPs. The T2 values of KB-HFAR cell pellets treated with
Fe3O4/PSS/G5.NHAc-FI-FA NPs dramatically decreased as a
function of Fe concentration (Table 2). In contrast, the de-
creasing trend of T2 values as a function of Fe concentration
for the same KB cells treated with Fe3O4/PSS/G5.NHAc-FI
NPs is significantly less than Fe3O4/PSS/G5.NHAc-FI-FA NPs.
In the T2-weighted spin-echo MR images (the color change
from red to purple indicates the gradual decrease of MR signal
intensity, which is similar to those reported based on the inten-
sity of black color.[11,12]) obtained using an Fe concentration of
11.3 lg mL–1, Fe3O4/PSS/G5.NHAc-FI-FA NPs reduces the
signal intensity to 50 % of the initial value (PBS control)
whereas Fe3O4/PSS/G5.NHAc-FI NPs reduces the signal to
about 89 % of the initial value (Fig. 6a). This suggested that
Fe3O4/PSS/G5.NHAc-FI-FA NPs can specifically hamper the
MR signal through FAR-mediated binding and endocytosis. At
higher Fe concentrations (e.g., 45 lg mL–1), non-specific bind-
ing of Fe3O4/PSS/G5.NHAc-FI NPs without FA conjugation
occurred with KB-HFAR cells. The dose-dependent quantita-
tive MR signal intensity shown in Figure 6b shows a significant
MR signal intensity decrease with the increase of Fe concentra-
tion for KB-HFAR cells incubated with Fe3O4/PSS/G5.NHAc-
FI-FA NPs. The non-specific uptake of Fe3O4/PSS/G5.NHAc-
FI NPs at higher Fe concentrations can also be inferred from
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Figure 4. Confocal microscopy images of KB-HFAR cells with different
treatments for 2 h. a) KB cells treated with PBS buffer; b) KB cells treated
with Fe3O4/PSS/G5.NHAc-FI NPs; and c) KB cells treated with Fe3O4/
PSS/G5.NHAc-FI-FA NPs. The nucleus of cells was blue-stained with
Hoescht33342. The green color was originated from the FI dye conjugated
on dendrimers.
Figure 5. TEM images of KB-HFAR cells treated with NPs for 2 h. a) and
b) KB cells treated with Fe3O4/PSS/G5.NHAc-FI-FA NPs; c) KB cells treat-
ed with Fe3O4/PSS/G5.NHAc-FI NPs. b) shows a magnified area of a typi-
cal vacuolar structure of a KB-HFAR cell.
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[a] Denotes Fe3O4/PSS/G5.NHAc-FI NPs.
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Figure 6b. Thus, lower concentrations of the Fe3O4 nanoparti-
cles provided better discrimination of KB-HFAR cells.
3. Conclusions
In summary, flow cytometry, confocal microscopy, TEM, and
MR imaging studies all demonstrated that Fe3O4/PSS/
G5.NHAc-FI-FA NPs specifically bind to KB-HFAR cells. In
contrast, Fe3O4/PSS/G5.NHAc-FI NPs that lack surface FA
moieties did not display binding to the KB cells, suggesting that
the binding was mediated by the FAR. The approach to func-
tionalizing Fe3O4 NPs using LbL self-assembly and dendrimer
chemistry may be applicable for various NPs and targeting
ligands (e.g., sugars, peptides, hormones and the like), thereby
providing a general strategy to fabricating various NPs for a
range of biological sensing and therapeutics applications. For
in vivo applications, the stability of the fabricated Fe3O4 NPs
may need to be further improved by increasing the polymer
layer thickness, which can be achieved by increasing the num-
ber of polymer layers via the LbL self-assembly technique. In
addition, the mechanical stability of the polymer coating may
also need to be improved through shell cross-linking. These ex-
periments and improvements are currently being developed in
our lab, and should provide a truly unique approach to func-
tionalized NPs.
4. Experimental
Materials: Ethylenediamine core amine-terminated PAMAM den-
drimers of generation 5 (G5.NH2) with a polydispersity index less than
1.08 were purchased from Dendritech (Midland, MI). FA, FI, Ferric
chloride hexahydrate (FeCl3 · 6H2O > 99 %), ferrous chloride tetrahy-
drate (FeCl2 · 4H2O > 99 %), sodium hydroxide, hydrochloric acid, and
all the other chemicals and solvents were pur-
chased from Aldrich (St. Louis, MO) and used
as received. KB cells were from American Type
Tissule Collection (ATCC, Rockville, Mary-
land). Penicillin, streptomycin, fetal bovine calf
serum (FBS) were purchased from Sigma (St.
Louis, MO). Trypsin-EDTA, Dulbecco’s PBS,
and RPMI 1640 medium (with or without FA)
was obtained from GIBCO-BRL (Gaithers-
burg, MD). Water used in all experiments was
purified using a Milli-Q Plus 185 water purifica-
tion system (Millipore, Bedford, MA) with re-
sistivity higher than 18 MX cm. Cellulose dialy-
sis membranes (MWCO = 10 000) were
acquired from Fisher.
Synthesis of Iron Oxide NPs: The Fe3O4 NPs
were synthesized by controlled co-precipitation
of FeII and FeIII ions according to a method de-
scribed elsewhere [33]. Briefly, 25 mL of 1 M
FeCl3 · 6H2O, 0.5 M FeCl2 · 4H2O and 0.4 M HCl
mixture solution was prepared in water under
vigorous stirring. The co-precipitation of Fe3O4
NPs was carried out in a three-neck round-bot-
tom flask. The above mixture solution was
added to 250 mL of 0.5 M NaOH, which was
preheated to 80 °C before the co-precipitation
reaction. The reaction was protected under N2
atmosphere and was vigorously stirred. Black
powder was collected by sedimentation with the help of an external
magnetic field and washed several times with water until stable ferro-
fluid was obtained. Finally, the particles were redispersed in water.
Synthesis of FI- and FA-Functionalized Dendrimers: Amine-termi-
nated G5 dendrimer (G5.NH2) was conjugated with FI or both FI and
FA moieties, according to previously published reports [29,46,47].
Briefly, G5.NH2 (60 mg, 0.00225301 mmol) was dissolved in anhydrous
DMSO (24 mL). To the above solution was added dropwise a solution
of FI (4.4 mg, 0.00563275 mmol) in DMSO (24 mL) under vigorous
stirring at room temperature. The reaction was stopped after 24 h. The
mixture was dialyzed against PBS buffer (3 times 4 l) and water (3
times 4 l) for 3 days through a 10 000 MWCO membrane. Lyophiliza-
tion gave G5.NH2-FI as an orange solid (60.6 mg, yield 94.0 %).
For the synthesis of G5.NH2-FI-FA, FA (3.7 mg, 0.0084004 mmol)
and EDC (9.3 mg, 0.021001 mmol) were dissolved in DMSO (3 mL)
and the mixture was stirred at room temperature for 3 h to activate the
c-carboxylic acid of FA. The resulting solution was added dropwise to a
solution of G5.NH2-FI (30 mg, 0.0010501 mmol) in DMSO (12 mL)
under vigorous stirring at room temperature. After 3 days, the reaction
mixture was dialyzed through a 10 000 MWCO membrane against PBS
buffer (3 times 4 l) and water (3 times 4 l) for 3 days, followed by lyo-
philization to give G5.NH2-FI-FA (31.2 mg, yield 96.4 %). The
G5.NH2-FI and G5.NH2-FI-FA conjugates were characterized by
1H
NMR, matrix-assisted laser desorption ionization-time of flight (MAL-
DI-TOF) mass spectrometry, and UV-vis spectrometry (Supporting In-
formation, Figs. S1–3) [29,46]. The numbers of FI and FA moieties con-
jugated onto each G5 dendrimer were estimated by comparing the
differences between the integration values of 1H NMR signals asso-
ciated with dendrimers and the FI and FA moieties. The average num-
bers of FI and FA moieties conjugated onto each G5 dendrimer were
estimated to be 4.5 and 4.8, respectively. The molecular weights of
G5.NH2-FI and G5.NH2-FI-FA conjugates were determined to be
29 564 and 33 484, respectively.
Fabrication of Multifunctional Dendrimer-Functionalized Iron Oxide
NPs: The LbL assembly of oppositely charged PSS and dendrimers was
performed according to the literature [20,23,48,49]. Briefly, a solution
of Fe3O4 NPs (5 mg in 0.5 mL water) was added with 1 mL of a PSS so-
lution (2 mg mL–1, containing 0.5 M NaCl) with occasional shaking.
After adsorption of PSS for 20 min, the suspension was centrifuged at
8000 rpm for 10 min. The supernatant was then carefully removed, and
the coated Fe3O4 NPs were washed by three alternate cycles of centri-
fuging and resuspending the particles in pure water. Then 1 mL of
3048 www.afm-journal.de © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2007, 17, 3043–3050



























Figure 6. MR imaging of KB-HFAR cell pellets incubated with functionalized Fe3O4 NPs. a) T2
weighted spin-echo images of cells incubated with functionalized Fe3O4 NPs with Fe concentra-
tions of 0, 11.3, 22.5, 45 lg mL–1. Left column, targeted denotes Fe3O4/PSS/G5.NHAc-FI-FA NPs.
Right column, non-targeted denotes Fe3O4/PSS/G5.NHAc-FI NPs. The color change from red to
purple indicates the gradual decrease of MR signal intensity. b) The percentage of signal intensity
compared to the cells in PBS was plotted as a function of the Fe concentration for both Fe3O4/
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G5.NH2-FI-FA solution (1 mg mL
–1, containing 0.5 M NaCl) was added
into the PSS-modified Fe3O4 NP suspension and purified in the same
manner. The PSS/G5.NH2-FI-FA-coated Fe3O4 NPs were subjected to
an acetylation reaction to neutralize the remaining amine groups of
G5.NH2-FI-FA dendrimers, using a procedure described elsewhere
[50]. In brief, the Fe3O4/PSS/G5.NH2-FI-FA NPs (in 1 mL water) were
added with triethylamine (2.48 lL) and mixed well. Then, a methanol
solution (0.1 mL) containing 1.82 mg acetic anhydride was added drop-
wise into the Fe3O4/PSS/G5.NH2-FI-FA NP/triethylamine solution.
The reaction mixture was vigorously shaken for 24 h. The formed
Fe3O4/PSS/G5.NHAc-FI-FA NPs were purified by 4 cycles of centrifu-
gation/washing/redispersion in water. For biological testing, the NPs
were transferred to PBS buffer solution by centrifugation and redisper-
sion. The NPs were stored at 4 °C before biological testing. The control
Fe3O4/PSS/G5.NHAc-FI NPs without FA conjugation were prepared
in the same manner as the procedure used to prepare Fe3O4/PSS/
G5.NHAc-FI-FA NPs.
General Characterization Methods: 1H NMR spectra of dendrimers
were recorded on a Bruker DRX 500 nuclear magnetic resonance spec-
trometer. Samples were dissolved in D2O before NMR measurements.
UV-vis spectra of dendrimers were collected using a Perkin Elmer
Lambda 20 UV-vis Spectrometer. All samples were dissolved in water
at the concentration of 1 mg mL–1. MALDI-TOF mass spectra were ac-
quired using a Micromass TofSpec-2E spectrometer (Beverly, MA) ac-
cording to a procedure described in our previous report [51]. The iron
concentration of Fe3O4 NPs before and after surface modification was
determined by an atomic absorption spectrometer (AA903, ARL).
A defined volume of the NPs were digested in 1.0 M nitric acid before
measurements. The surface potential of functionalized Fe3O4 NPs was
measured by a Malvern Zetasizer Nano ZS model ZEN3600 (Worces-
tershire, UK) equipped with a standard 633 nm laser. The size and mor-
phology of Fe3O4 NPs were characterized by a Philips CM-100 TEM
equipped with a Hamamatsu Digital Camera ORCA-HR operated
using AMT software (Advanced Microscopy Techniques Corp, Danver,
MA). The operation voltage was kept at 60 kV. TEM samples were
prepared by deposition of a diluted particle suspension (5 lL) onto a
carbon-coated copper grid and air-dried before the measurement.
Stained specimens were prepared by depositing the sample solutions
on the grid and inverting the grid on a drop of aqueous phosphotungs-
tic acid solution that had been neutralized with NaOH (2 % mass frac-
tion of phosphotungstic acid). The grid was then blotted on filter paper
and air-dried. The size distribution histogram of Fe3O4 NPs was mea-
sured using ImageJ software (http://rsb.info.nih.gov/ij/download.html).
For each sample, 300 nanoparticles were randomly selected to analyze
the size.
KB Cell Culture: The KB cells were continuously grown in two
24-well plates, one in FA-free media and the other in regular RPMI
1640 medium supplemented with penicillin (100 units mL–1), strepto-
mycin (100 lg mL–1), 10 % heat-inactivated FBS, and 2.5 lM FA. The
cells grown in FA-free media express high-level FAR, while the cells
grown in FA-containing media express low-level FAR.
Determination of Cell Viability: Cell viability was measured by fluo-
rescein diacetate (FDA) and propidium iodide (PI) staining. FDA
stains live cells, while PI stains dead cells. The stained cells were quanti-
fied by flow cytometry as described by Killinger [52]. Briefly, 6 × 104
KB cells per well were seeded into a 24-well plate and incubated with
0–150 lg mL–1 of unmodified Fe3O4 NPs, Fe3O4/PSS/G5.NHAc-FI
NPs, and Fe3O4/PSS/G5.NHAc-FI-FA NPs for 24 h at 37 °C. Ten thou-
sand cells were acquired from each sample for flow cytometric analysis.
The morphology of cells treated with functionalized Fe3O4 NPs with Fe
concentrations of 0, 22.5, 50, and 150 lg mL–1 were observed by a
phase-contrast microscopy (Leica DMIRB fluorescent inverted micro-
scope). The magnification is set at 200× for all samples.
Determination of Binding Affinity by Flow Cytometry: Approxi-
mately 1 × 105 cells per well were seeded in 24-well plates the day be-
fore the experiments. An hour before initiating an experiment, the cells
were rinsed four times with serum-free and FA-deficient RPMI 1640
media. Fe3O4/PSS/G5.NHAc-FI and Fe3O4/PSS/G5.NHAc-FI-FA NPs
were added at Fe concentrations of 0–90 lg mL–1. After 1 h incubation
at 37 °C, KB cells with both high- and low-level FAR were trypsinized
and suspended in PBS containing 0.1 % bovine serum albumin, and
then analyzed using a Coulter EPICS-XL MCL Beckman-Coulter flow
cytometer. The FL1-fluorescence of 10 000 cells was measured, and the
mean fluorescence of gated viable cells was quantified using Expo32
software (Beckman-Coulter, Miami, FL).
Confocal Laser Scanning Microscopy: Confocal microscopic analysis
was performed in cells plated on a plastic cover-slip using an Olympus
FluoView 500 laser scanning confocal microscope (Melville, NY). FI
fluorescence was excited with a 488 nm argon blue laser and emission
was measured through a 505–525 barrier filter. The optical section
thickness was set at 5 lm. The KB-HFAR cells were incubated with
Fe3O4/PSS/G5.NHAc-FI or Fe3O4/PSS/G5.NHAc-FI-FA NPs for 2 h
at 37 °C. Then the cells were washed with PBS. The nuclei were coun-
terstained with 1 lg mL–1 of Hoescht33342, using a standard procedure.
Samples were scanned on an Olympus IX-71 inverted microscope,
using a 60× water immersion objective and magnified with FluoView
software.
Transmission Electron Microscopy (TEM): The uptake of functional-
ized Fe3O4 NPs was further examined by a Phillips CM 100 TEM mi-
croscope operating at a voltage of 60 kV. Images were recorded using a
Hamamatsu digital camera controlled by AMT (advance microscopy
technology) software. The KB-HFAR cells were incubated with Fe3O4/
PSS/G5.NHAc-FI or Fe3O4/PSS/G5.NHAc-FI-FA NPs for 2 h at 37 °C.
The medium was then removed and the cells were washed with Soren-
son buffer and fixed at room temperature for 1 h using 2.5 % of glutar-
aldehyde in Sorenson buffer. The cells were rinsed 3 times with Soren-
son buffer, resuspended in the same medium, and post-fixed using
1.0 % osmium tetroxide for 1 h. After additional washing in buffer, the
cells were dehydrated in a series of ethanol solutions of 30 %, 50 %,
70 %, 95 %, and 100 %. Samples were further infiltrated using the fol-
lowing sequence of mixtures of 100 % ethanol and Epon: 3 parts of eth-
anol + 1 part resin (for 1 h), 1 part of ethanol + 1 part resin (for 1 h), 1
part of ethanol + 3 parts resin (overnight), full-strength resin (4 h), and
full-strength resin (overnight). After the third change of resin, polymer-
ization was performed and sections with a thickness of 75 nm were ob-
tained using a Reichart Ultramicrotom. Sections were mounted on 200
mesh copper grids before TEM measurements.
In Vitro MR Relaxometry and Imaging: 5 × 106 KB-HFAR cells were
incubated with Fe3O4/PSS/G5.NHAc-FI and Fe3O4/PSS/G5.NHAc-FI-
FA NPs with Fe concentrations of 11.3, 22.5, and 45 lg mL–1 for 30 min
in an ice bath. Live cells are usually cultured with a complete medium
at 37 °C. For the MRI studies, live cells were trypsinized and suspended
in PBS (instead of cell culture medium) and incubated with NPs. Live
cells in PBS have a higher viability at 4 °C or in an ice bath than at
room temperature, so we incubated cells with NPs in an ice bath. The
cells were then washed with PBS buffer three times. The cells were cen-
trifuged to prepare pellets for MR imaging. Studies were performed
with a 2.0 T Varian Unity/Inova system (Palo Alto, CA) using home-
built RF coils. One hundred microliters of PBS was added to each cell
pellet, and the cells were suspended by gentle shaking. T1 and T2 of
the cell suspensions were measured in each sample vial with inversion
recovery and CPMG pulse sequences, respectively. The cells were then
allowed to settle and a phantom was constructed consisting of all of the
sample vials. A spin-echo image (TR/TE 2000/8 ms) with a 2.0 mm-
slice thickness and an in-plane resolution of 0.312 mm was acquired
through the plane of the cells.
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